BRPI0818672A2 - 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase - Google Patents

2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase

Info

Publication number: BRPI0818672A2
Authority: BR; Brazil
Prior art keywords: deoxitetrahydrouridines; desaminase; citidine; fluor; inhibitors
Prior art date: 2007-10-16

Application number

BRPI0818672-3A

Other languages

English (en)

Inventor

Gregory S Hamilton

Takashi Tsukamoto

Dana V Ferraris

Bridget Duvall

Rena Lapidus

Original Assignee

Eisai Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-16

Filing date

2008-10-16

Publication date

2015-04-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818672(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-16 Application filed by Eisai Inc filed Critical Eisai Inc

2015-04-14 Publication of BRPI0818672A2 publication Critical patent/BRPI0818672A2/pt

2020-10-20 Publication of BRPI0818672B1 publication Critical patent/BRPI0818672B1/pt

2021-05-25 Publication of BRPI0818672B8 publication Critical patent/BRPI0818672B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0818672A 2007-10-16 2008-10-16 composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas BRPI0818672B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US98039707P	2007-10-16	2007-10-16
US60/980,397		2007-10-16
PCT/US2008/080163 WO2009052287A1 (en)	2007-10-16	2008-10-16	2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Publications (3)

Publication Number	Publication Date
BRPI0818672A2 true BRPI0818672A2 (pt)	2015-04-14
BRPI0818672B1 BRPI0818672B1 (pt)	2020-10-20
BRPI0818672B8 BRPI0818672B8 (pt)	2021-05-25

Family

ID=40251685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818672A BRPI0818672B8 (pt)	2007-10-16	2008-10-16	composições, composições farmacêuticas e usos de 2'flúor-2'-desoxitetra-hidrouridinas

Country Status (38)

Country	Link
US (4)	US8268800B2 (pt)
EP (2)	EP2207786B1 (pt)
JP (2)	JP5496899B2 (pt)
KR (1)	KR101543049B1 (pt)
CN (1)	CN101827856B (pt)
AT (1)	ATE548374T1 (pt)
BR (1)	BRPI0818672B8 (pt)
CA (1)	CA2702274C (pt)
CO (1)	CO6270330A2 (pt)
CR (1)	CR11427A (pt)
CY (3)	CY1112781T1 (pt)
DK (1)	DK2207786T3 (pt)
EA (1)	EA018757B1 (pt)
EC (1)	ECSP10010095A (pt)
ES (2)	ES2384011T3 (pt)
FI (2)	FIC20230039I1 (pt)
FR (2)	FR23C1052I2 (pt)
GT (1)	GT201000088A (pt)
HR (1)	HRP20120419T1 (pt)
HU (2)	HUS2300044I1 (pt)
IL (1)	IL204732A (pt)
JO (1)	JO2778B1 (pt)
ME (1)	ME00997B (pt)
MX (1)	MX2010004109A (pt)
MY (1)	MY147970A (pt)
NI (1)	NI201000055A (pt)
NL (1)	NL301256I2 (pt)
NO (2)	NO2023047I1 (pt)
NZ (1)	NZ584229A (pt)
PL (1)	PL2207786T3 (pt)
PT (1)	PT2207786E (pt)
RS (1)	RS52323B (pt)
SA (1)	SA08290661B1 (pt)
SI (1)	SI2207786T1 (pt)
TW (1)	TWI445539B (pt)
UA (1)	UA99476C2 (pt)
WO (1)	WO2009052287A1 (pt)
ZA (1)	ZA201002178B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain Compounds, Compositions and Methods
JP2011520880A (ja)	2008-05-15	2011-07-21	セルジーンコーポレイション	シチジン類似体の経口製剤およびその使用方法
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
US20100055047A1 (en) *	2008-08-26	2010-03-04	Yiyu Zou	Methods for treating bronchial premalignancy and lung cancer
KR20110104074A (ko) *	2008-12-23	2011-09-21	파마셋 인코포레이티드	퓨린 뉴클레오시드의 합성
CA2757745C (en) *	2009-04-06	2018-02-13	Eisai Inc.	Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
CA2757744C (en) *	2009-04-06	2018-02-13	Eisai Inc.	Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
ES2593088T3 (es) *	2009-04-06	2016-12-05	Otsuka Pharmaceutical Co., Ltd.	Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer
GB0907551D0 (en)	2009-05-01	2009-06-10	Univ Dundee	Treatment or prophylaxis of proliferative conditions
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
CL2011000716A1 (es)	2010-03-31	2012-04-20	Gilead Pharmasset Llc	Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
PL3290428T3 (pl)	2010-03-31	2022-02-07	Gilead Pharmasset Llc	Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
EP3042910B1 (en)	2010-11-30	2019-01-09	Gilead Pharmasset LLC	2'-spiro-nucleosides for use in the therapy of hepatitis c
MX354958B (es)	2011-09-16	2018-03-27	Gilead Pharmasset Llc	Metodos para el tratamiento de vhc.
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
KR101962522B1 (ko)	2013-01-31	2019-03-26	길리애드 파마셋 엘엘씨	두 항바이러스 화합물의 병용 제형물
AU2014311827B2 (en)	2013-08-27	2017-09-14	Gilead Sciences, Inc.	Combination formulation of two antiviral compounds
EP3063164B1 (en)	2013-10-29	2018-12-05	Otsuka Pharmaceutical Co., Ltd.	Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
KR102456088B1 (ko)	2014-04-04	2022-10-19	델 마 파마슈티컬스	폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
JP7120763B2 (ja)	2014-08-22	2022-08-17	セルジーンコーポレイション	免疫調節化合物を抗体と併用する多発性骨髄腫の治療方法
US11376270B2 (en) *	2015-12-03	2022-07-05	Epidestiny, Inc.	Compositions containing decitabine, 5Azacytidine and tetrahydrouridine and uses thereof
WO2017158396A1 (en) *	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
CA3091027A1 (en)	2018-02-02	2019-08-08	Maverix Oncology, Inc.	Small molecule drug conjugates of gemcitabine monophosphate
CN113227755B (zh) *	2018-08-28	2025-06-27	上海宜晟生物科技有限公司	测定准确度改善
US11224610B2 (en) *	2018-09-19	2022-01-18	Otsuka Pharmaceutical Co., Ltd.	Low dose combination CDA substrate drug/cedazuridine with extended administration
KR102280330B1 (ko) *	2018-10-19	2021-07-21	인터올리고 주식회사	치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
JP7433662B2 (ja) *	2018-10-19	2024-02-20	インターオリゴ・コーポレイション	治療効能を改善した核酸変形体及びそれを含む抗癌用薬学組成物
KR20220078619A (ko) *	2019-10-08	2022-06-10	오츠카 세이야쿠 가부시키가이샤	고순도의 2'-데옥시-2',2'-디플루오로테트라히드로우리딘 및 그의 제조 방법
CA3163122A1 (en)	2020-02-25	2021-09-02	Aram Oganesian	Combination decitabine and cedazuridine solid oral dosage forms
MX2023011120A (es) *	2021-03-26	2023-10-03	Cleveland Clinic Found	Tratamiento de la infeccion por virus de arn con un inhibidor de citidina deaminasa.
WO2022254457A1 (en) *	2021-05-29	2022-12-08	Msn Laboratories Private Limited, R&D Center	An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
MX2024004801A (es)	2021-10-19	2024-06-28	Akirabio Inc	Composiciones que comprenden análogos de 2'- desoxicitidina, y uso de las mismas para el tratamiento de anemia de células falciformes, talasemia y cánceres.
WO2023076332A1 (en) *	2021-11-01	2023-05-04	St. John's University	Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) *	2021-12-25	2023-08-31	Scinopharm Taiwan, Ltd.	Process for preparing cedazuridine
AU2022476674A1 (en)	2022-08-31	2025-04-17	Taiho Pharmaceutical Co., Ltd.	Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4017606A (en) *	1973-10-04	1977-04-12	The Upjohn Company	Organic compounds and process
US4210638A (en) *	1978-03-17	1980-07-01	Pcr, Inc.	Antiviral composition and method of treating virus diseases
US4275057A (en)	1980-01-28	1981-06-23	The United States Of America As Represented By The Department Of Health, Education And Welfare	Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en)	1983-03-10	1985-07-02	Eli Lilly And Company	Difluoro antivirals and intermediate therefor
WO1985001871A1 (en)	1983-10-26	1985-05-09	Greer Sheldon B	Method and materials for sensitizing neoplastic tissue to radiation
CA1264738A (en) *	1984-12-04	1990-01-23	Eli Lilly And Company	Treatment of tumors in mammals
US4965374A (en) *	1987-08-28	1990-10-23	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) *	1987-08-28	1993-06-29	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en)	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
EP0543976A4 (en)	1991-04-23	1993-11-10	Oglevee, Ltd.	In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) *	1991-10-08	1993-12-10	Commissariat A Energie Atomique	Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5821357A (en) *	1992-06-22	1998-10-13	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5594124A (en) *	1992-06-22	1997-01-14	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5426183A (en) *	1992-06-22	1995-06-20	Eli Lilly And Company	Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) *	1992-06-22	1997-02-25	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5371210A (en) *	1992-06-22	1994-12-06	Eli Lilly And Company	Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
CA2118490A1 (en) *	1993-02-23	1994-09-01	Lawrence C. Sowers	4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) *	1993-05-14	1994-11-24	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) *	1993-06-01	1993-07-21	Hafslund Nycomed As	Cell growth regualtors
US5637688A (en) *	1994-12-13	1997-06-10	Eli Lilly And Company	Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) *	1995-01-18	1996-05-28	Eli Lilly And Company	2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) *	1995-03-01	1996-09-06	Human Gene Therapy Research Institute	Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) *	1995-12-13	1999-12-14	Eli Lilly And Company	Process for making gemcitabine hydrochloride
US5760208A (en) *	1996-08-14	1998-06-02	The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations	Process to prepare pyrimidine nucleosides
EP1156827B1 (en) *	1999-03-01	2006-09-20	Halogenetics, Inc.	USE OF COMPOSITIONS COMPRISING CldC AS RADIOSENSITIZERS IN THE TREATMENT OF NEOPLASTIC DISEASES
US6933287B1 (en) *	1999-03-01	2005-08-23	Sheldon B. Greer	Dramatic simplification of a method to treat neoplastic disease by radiation
WO2001013789A1 (en)	1999-08-26	2001-03-01	Aortech International Plc	Improvements relating to catheter positioning
US6462191B1 (en) *	2000-07-13	2002-10-08	Air Products And Chemicals, Inc.	Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN102241720B (zh)	2000-11-29	2014-01-29	三井化学株式会社	L-核酸衍生物及其合成方法
WO2002056912A2 (en) *	2001-01-16	2002-07-25	Glaxo Group Limited	Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP2322534A1 (en)	2001-05-18	2011-05-18	Rakesh Kumar	Antiviral nucleosides
AU2002322805B2 (en) *	2001-07-31	2007-11-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Inhibitor of DNA methylation
US20040002476A1 (en)	2002-02-14	2004-01-01	Stuyver Lieven J.	Modified fluorinated nucleoside analogues
US6982253B2 (en)	2002-06-05	2006-01-03	Supergen, Inc.	Liquid formulation of decitabine and use of the same
CA2499036A1 (en)	2002-09-24	2004-04-08	Koronis Pharmaceuticals, Incorporated	1,3,5-triazines for treatment of viral diseases
EP1567169A4 (en)	2002-11-04	2009-10-21	Xenoport Inc	GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
WO2005115410A2 (en)	2004-05-06	2005-12-08	University Of Rochester	Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en)	2004-07-13	2006-01-19	Supergen Inc.	Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (en)	2004-07-30	2006-02-09	Pharmaessentia Corp.	STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
KR20070073958A (ko)	2004-12-08	2007-07-10	시코르, 인크.	디플루오로뉴클레오시드 및 이의 제조 방법
WO2008085611A2 (en) *	2006-11-27	2008-07-17	University Of Miami	Designer theraphy of pancreatic tumors
WO2009021551A1 (en)	2007-08-13	2009-02-19	Universite De La Mediterranee	A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain Compounds, Compositions and Methods
WO2010047698A1 (en)	2008-10-22	2010-04-29	University Of Alabama At Birmingham	Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
CA2757745C (en) *	2009-04-06	2018-02-13	Eisai Inc.	Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
ES2593088T3 (es) *	2009-04-06	2016-12-05	Otsuka Pharmaceutical Co., Ltd.	Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer
CA2757744C (en) *	2009-04-06	2018-02-13	Eisai Inc.	Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer

2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2008-10-16 CA CA2702274A patent/CA2702274C/en active Active
- 2008-10-16 RS RS20120232A patent/RS52323B/en unknown
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/en active Application Filing
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/me unknown
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-16 EP EP08840633A patent/EP2207786B1/en active Active
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/en active Active
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active Active
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
2012
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
2023
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-22 CY CY2023028C patent/CY2023028I1/el unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-22 CY CY2023029C patent/CY2023029I1/el unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-26 FR FR23C1052C patent/FR23C1052I2/fr active Active
- 2023-12-26 FR FR23C1051C patent/FR23C1051I2/fr active Active
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown

Also Published As

Publication number	Publication date
EP2207786B1 (en)	2012-03-07
EP2447272A1 (en)	2012-05-02
PT2207786E (pt)	2012-05-28
US20140186335A1 (en)	2014-07-03
ME00997B (me)	2012-10-20
IL204732A0 (en)	2010-11-30
ES2384011T3 (es)	2012-06-28
US9567363B2 (en)	2017-02-14
ZA201002178B (en)	2011-05-25
CN101827856A (zh)	2010-09-08
FIC20230040I1 (fi)	2023-12-22
HRP20120419T1 (hr)	2012-07-31
KR20100091978A (ko)	2010-08-19
US20120289475A1 (en)	2012-11-15
JP2011500713A (ja)	2011-01-06
EA018757B1 (ru)	2013-10-30
AU2008312435B2 (en)	2014-04-17
JP5859588B2 (ja)	2016-02-10
MX2010004109A (es)	2010-08-10
KR101543049B1 (ko)	2015-08-07
AU2008312435A1 (en)	2009-04-23
NZ584229A (en)	2012-06-29
FIC20230039I1 (fi)	2023-12-22
NO2023048I1 (en)	2023-12-21
JO2778B1 (en)	2014-03-15
CO6270330A2 (es)	2011-04-20
FR23C1051I1 (fr)	2024-01-26
FR23C1052I2 (fr)	2025-02-07
NL301256I2 (nl)	2024-01-11
TWI445539B (zh)	2014-07-21
HUS2300044I1 (hu)	2024-01-28
ES2616566T3 (es)	2017-06-13
MY147970A (en)	2013-02-28
SI2207786T1 (sl)	2012-10-30
BRPI0818672B8 (pt)	2021-05-25
IL204732A (en)	2013-07-31
CY1112781T1 (el)	2016-02-10
NL301256I1 (pt)	2024-01-03
US8951987B2 (en)	2015-02-10
WO2009052287A1 (en)	2009-04-23
CN101827856B (zh)	2013-02-06
ATE548374T1 (de)	2012-03-15
FR23C1052I1 (fr)	2024-01-26
US20150210730A1 (en)	2015-07-30
GT201000088A (es)	2012-03-13
RS52323B (en)	2012-12-31
US8268800B2 (en)	2012-09-18
AU2008312435A8 (en)	2014-07-24
US20090137521A1 (en)	2009-05-28
CR11427A (es)	2010-08-16
EA201000642A1 (ru)	2010-10-29
JP2014177455A (ja)	2014-09-25
HK1146410A1 (en)	2011-06-03
CA2702274A1 (en)	2009-04-23
NI201000055A (es)	2010-08-13
US8618075B2 (en)	2013-12-31
CA2702274C (en)	2015-12-29
CY2023028I1 (el)	2024-02-16
EP2207786A1 (en)	2010-07-21
UA99476C2 (en)	2012-08-27
BRPI0818672B1 (pt)	2020-10-20
NO2023047I1 (no)	2023-12-21
TW200924786A (en)	2009-06-16
EP2447272B1 (en)	2017-02-01
ECSP10010095A (es)	2010-07-30
JP5496899B2 (ja)	2014-05-21
PL2207786T3 (pl)	2012-09-28
HUS2300045I1 (hu)	2024-01-28
DK2207786T3 (da)	2012-06-18
FR23C1051I2 (fr)	2025-02-07
CY2023029I1 (el)	2024-02-16
SA08290661B1 (ar)	2012-06-10

Publication	Publication Date	Title
BRPI0818672A2 (pt)	2015-04-14	2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
NO20084334L (no)	2008-11-27	Farmasoytiske sammensetninger
PA8667201A1 (es)	2006-10-13	Nuevos compuestos farmaceuticos
MY153915A (en)	2015-04-15	Organic compounds
ECSP11010885A (es)	2011-04-29	Heteroarilos sustituidos
CY1109916T1 (el)	2014-09-10	Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
MA32508B1 (fr)	2011-07-03	Composes organiques
ATE502921T1 (de)	2011-04-15	Substituierte indole
CR20110028A (es)	2011-04-07	Derivados de pirimidina como inhibidores de cinasa
EA200900798A1 (ru)	2010-10-29	Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
DOP2006000061A (es)	2006-09-30	Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
PA8792401A1 (es)	2009-03-31	Fenilendiaminas
ECSP088749A (es)	2008-10-31	Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
EA200971068A1 (ru)	2010-04-30	Триазолиламинопиримидиновые соединения
PA8855001A1 (es)	2010-07-27	Monocarbamas
ATE430148T1 (de)	2009-05-15	Neue pyrrolodihydroisochinoline als pde10- inhibitoren
EA201000069A1 (ru)	2011-02-28	Новые гербициды
DOP2009000214A (es)	2009-10-31	Macrolidos basados en eritromicina
NO20091386L (no)	2009-05-06	Fenyloksyanilinderivater
FR2907121B1 (fr)	2012-05-04	Nouveaux derives morphiniques
ATE534638T1 (de)	2011-12-15	Piperazin-derivate

Legal Events

Date	Code	Title	Description
2016-03-29	B25A	Requested transfer of rights approved	Owner name: OTSUKA PHARMACEUTICAL CO., LTD (JP)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2020-02-18	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-05-26	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-08-25	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-10-20	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF